
Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.
Rick Chapman brings decades of health economics and outcomes research (HEOR) expertise to his role as Chief Science Officer. Chapman was Director of Health Economics at the Institute for Clinical and Economic Review prior to the Center for Innovation & Value Research, where he led development of economic evaluations that accompanied rigorous reviews of clinical evidence. Formerly, he was VP of HEOR at Avalere Health. Before that, Chapman was a principal in HEOR at IMS Health, and a research analyst at the Center for Risk Analysis at the Harvard School of Public Health.Chapman holds a PhD in health policy with a concentration in decision sciences from Harvard University. He also holds an MS in health policy and management from the Harvard School of Public Health.
Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.
Published: March 13th 2025 | Updated:
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.